Koronis Pharma, Inc. develops antiviral therapeutics based on Viral Decay Acceleration™ (VDA) - a novel drug mechanism. The Company's lead product candidate is
KP-1461 for the treatment of HIV.
- Viral Decay Acceleration exploits the strength of a virus – its high mutation rate – to target its collapse. Learn more
- Stay Informed by joining our email distribution list to receive the latest announcements from Koronis, including company alerts and press releases.
Revolutionizing HIV Therapeutics
Viral Decay Acceleration™ Animation
Viral Fitness & Mutagenesis Animation
click the
icon in the player.